Skip to main content
. Author manuscript; available in PMC: 2016 Feb 15.
Published in final edited form as: Int J Cancer. 2014 Jun 28;136(3):536–546. doi: 10.1002/ijc.29028

Figure 2. Interruption of KLF5 acetylation reverses its activity from tumor suppressing to tumor promoting in prostate cancer cells.

Figure 2

Cancer cells expressing KLF5, acetylation-deficient K369R, or the vector control (PLHCX) were subcutaneously injected into nude mice, and tumors were surgically isolated at day 35 for PC-3 cells (a) and day 38 for DU 145 cells (b) post injection. The average tumor weight (grams, g) is shown in the bar figures at left, with the standard error indicated at the top of each bar. Images of all tumors are shown at right. *, P<0.05; ***, P<0.0001.